Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome

被引：39

作者：

Al-Ahmari, Ali ^{[1
]}

Shah, Niketa ^{[1
]}

Sung, Lillian ^{[1
]}

Zipursky, Alvin ^{[1
]}

Hitzler, Johann ^{[1
]}

机构：

[1] Univ Toronto, Div Hematol Oncol, Hosp Sick Children, Toronto, ON M5G 1X8, Canada

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2006年 / 133卷 / 06期

关键词：

Down syndrome; acute megakaryoblastic leukaemia; treatment; low-dose chemotherapy; cytarabine;

D O I：

10.1111/j.1365-2141.2006.06097.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Children with acute megakaryoblastic leukaemia (AMKL) and Down syndrome (DS) show a favourable response to chemotherapy, probably due to increased sensitivity of the leukaemic blasts to cytarabine. In contrast, dose-intensive approaches have resulted in disproportionate treatment-related mortality in this group. The survival of children with AMKL and DS was retrospectively compared following treatment with a low-dose chemotherapy protocol, consisting of cytarabine (10 mg/m(2)/dose), retinylpalmitate and vincristine or standard chemotherapy. Event-free (67 +/- 11%) and overall survival (77 +/- 10%) at 5 years were not significantly different in both groups. Further reduction of treatment intensity in AMKL of children with DS, therefore, appears feasible.

引用

页码：646 / 648

页数：3

共 12 条

[1] AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity [J].

Creutzig, U ;

Reinhardt, D ;

Diekamp, S ;

Dworzak, M ;

Stary, J ;

Zimmermann, M .

LEUKEMIA, 2005, 19 (08) :1355-1360

[2] Increased age at diagnosis has a significantly negative effect on outcome in children with down syndrome and acute myeloid leukemia: A report from the Children's Cancer Group Study 2891 [J].

Gamis, AS ;

Woods, WG ;

Alonzo, TA ;

Buxton, A ;

Lange, B ;

Barnard, DR ;

Gold, S ;

Smith, FO .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) :3415-3422

[3] GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia [J].

Ge, YB ;

Stout, ML ;

Tatman, DA ;

Jensen, TL ;

Buck, SA ;

Thomas, RL ;

Ravindranath, Y ;

Matherly, LH ;

Taub, JW .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (03) :226-231

[4] The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines [J].

Ge, YB ;

Jensen, TL ;

Stout, ML ;

Flatley, RM ;

Grohar, PJ ;

Ravindranath, Y ;

Matherly, LH ;

Taub, JW .

CANCER RESEARCH, 2004, 64 (02) :728-735

[5] Origins of leukaemia in children with Down syndrome [J].

Hitzler, JK ;

Zipursky, A .

NATURE REVIEWS CANCER, 2005, 5 (01) :11-20

[6]

KUDO K, 2005, ANN M AM SOC HEM, pA84

[7]

Lange BJ, 1998, BLOOD, V91, P608

[8]

RAVINDRANATH Y, 1992, BLOOD, V80, P2210

[9] Erythroblastic and/or megakaryoblastic leukemia in Down syndrome: Treatment with low-dose arabinosyl cytosine [J].

Tchernia, G ;

Lejeune, F ;

Boccara, JF ;

Denavit, MF ;

Dommergues, JP ;

Bernaudin, F .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1996, 18 (01) :59-62

[10] The treatment of children with acute megakaryoblastic leukemia who have Down syndrome [J].

Zipursky, A .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1996, 18 (01) :10-12

← 1 2 →